Shanghai Securities released a research report on April 28 stating that it gave Jiangsu Wu Zhong (600200.SH) a buy rating. The main reasons for the rating include: 1) the company's medical and aesthetic product Aesofei has been officially approved and is expected to be marketed quickly; 2) increasing investment in independent research and development to further lay out the field of recombinant collagen. (Mainichi Keizai Shimbun)
上海证券4月28日发布研报称，给予江苏吴中（600200.SH）买入评级。评级理由主要包括：1）公司医美产品艾塑菲正式获批，期待上市快速放量；2）加大自主研发投入，深度布局重组胶原蛋白领域。（每日经济新闻）
Shanghai Securities released a research report on April 28 stating that it gave Jiangsu Wu Zhong (600200.SH) a buy rating. The main reasons for the rating include: 1) the company's medical and aesthetic product Aesofei has been officially approved and is
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Investment Course
Choose stocks based on financial reports
Quickly master financial season learning guidelines
When the financial season comes, company stock prices are the most likely to rise and fall, and many excellent investors will see the financial season as a good
How to view Tesla's performance in January 2025? Pay attention to these four key points.
It's earnings season for US stocks again. The performance of giant companies not only affects their own stock prices but also influences the overall trend of th
In 【2024.11】, surged more than 0.04 million times, achieving the title of stock god Buffett! How do you view Berkshire's performance?
When it comes to legendary figures in the investment world, the name of Warren Buffett, the helm of Berkshire Hathaway, is definitely unavoidable. $Berkshire Ha